Leidos (LDOS) Q2 FY26 earnings call: guidance and Q&A

Analyst asked about the DHA's decision to integrate MHS GENESIS internally and if this indicates a broader trend of agencies limiting systems integrators' roles.

Management confirmed a trend towards in-sourcing systems integration and commercial tech acquisition across agencies but noted that Leidos transitions its value-added services to higher-level mission systems integration. They emphasized that agencies still need partners for maintenance and enhancement, and Leidos is well-positioned to continue support.

“I think, honestly, the trend here is that there is an interest in-sourcing across many government agencies right now. What they're interested in-sourcing is the systems integration, as you say, but also the acquisition of commercial technology per the aspirations of this administration.”

asked by Scott Mikus · answered by Thomas Bell

Analyst inquired about the implications of the VA suspending incentive payments for the VBA medical disability exam business for 2027 and the future margin outlook for the Health segment.

Management stated the incentive payment suspension is for this year only due to administrative issues, and they expect incentives to be part of the next contract. They anticipate a contract extension through early 2027 and believe their strengths in quality and timeliness will ensure competitiveness. The Q4 FY26 performance is a good baseline for 2027, and other growth pillars will offset Health segment changes.

“It's been very clear that that's for this year only. And I was just with the leadership of the Veterans Administration yesterday to seek clarity on where all this is going. And it became clear in that conversation that while cost is one concern the veterans administration has, value better in experience, quality are still things that they are very, very keenly focused on.”

asked by Matthew Akers · answered by Thomas Bell

Analyst asked about key levers for free cash flow growth, associated risks, and sponsor interest in sub-portfolio assets.

Management expressed satisfaction with record Q2 free cash flow and raised full-year guidance, partly due to reduced CapEx. They highlighted the low capital intensity of the business and ongoing efforts to improve DSO. Regarding M&A, they are actively surveying the landscape but will remain disciplined, focusing on current integrations and the SES joint venture.

“So this is a cash-generating business. It will continue to be a cash-generating business. And beyond that, we've got our enterprise transformation office working hand in glove with my team on how do we take days out of our DSO performance.”

asked by Colin Canfield · answered by Chris Cage

Analyst asked about the cadence of award activity in the Intelligence and Digital business through year-end and the pace of conversion to fixed-price contracts.

Management confirmed accelerating customer activity, evident in strong book-to-bill, and expects continued positive bookings momentum. They noted the administration's push to obligate funds, supporting second-half bookings. They welcome fixed-price contracts, seeing it as a strength, and are actively positioning in cyber, secure cloud, and AI for the intelligence community.

“From a macro lens, this administration is obviously anxious to demonstrate to the public that they can deliver in advance of the November midterms. And so you hear Secretary for instance, projecting that the vast majority of his unobligated funds from the reconciliation budget of 2025 will be on contract before October 1.”

asked by Seth Seifman · answered by Thomas Bell

Analyst sought perspective on future opportunities in the Defense business beyond current programs and how increased hardware mix impacts margins.

Management is very bullish on Defense Tech, expanding growth engines to include munitions and counter-UAS. They detailed programs like IFPC, small cruise missile (Sphere), and low-cost containerized munitions, citing a $44 billion addressable market over 10 years. They expect double-digit profitability and CAGR for Defense, with margins accelerating as programs mature and quantities increase.

“All told, the addressable markets that we're talking about here just for low-cost and containerized munitions is in excess of $44 billion over the next 10 years.”

asked by Tobey Sommer · answered by Thomas Bell

Analyst asked for clarity on the expected timing of the VBA recompete RFP and if there's an opportunity to invest and improve margins if there's a reset.

Management expects a draft RFP 'any day,' leading to a formal RFP in 30-60 days, with decisions likely early next year. They anticipate current contracts to be extended through early to mid-2027. They affirmed their commitment to investing in the business to maintain technology, volume, and quality leadership, believing this differentiation will allow them to play a strong game in outcome-based contracting.

“By the time we talk on our next earnings call, I expect to have a firm RFP and understand exactly what that business is going to look like going forward. But in the meantime, even the runway for 2027 is starting to clear up because we see the international and predischarge probably extended through September 2027.”

asked by Gavin Parsons · answered by Thomas Bell

Analyst asked about the balance between growth investments, M&A, and share repurchases, especially given the current valuation.

Management reiterated a balanced approach to capital allocation. While leaning into defense tech investments, they emphasized low capital intensity overall. They noted M&A targets are currently expensive relative to Leidos' valuation, making share repurchases more attractive. They confirmed a new $20 million share repurchase authorization and commitment to deploying capital intelligently.

“The Board authorized a new $20 million share repurchase program on Friday. You can expect us to continue to deploy capital equally around the pitch. M&A targets right now are very expensive, and our valuation is not.”

asked by John Godyn · answered by Thomas Bell